Case 3 - Agnieszka Glowniak - The knee that wouldn't let go
A persistent knee monoarthritis in a 42M
Received amox/clav, then steroids, then MTX
#ACR26 #GlobalSummit
A persistent knee monoarthritis in a 42M
Received amox/clav, then steroids, then MTX
#ACR26 #GlobalSummit
November 6, 2026 at 5:04 PM
Case 3 - Agnieszka Glowniak - The knee that wouldn't let go
A persistent knee monoarthritis in a 42M
Received amox/clav, then steroids, then MTX
#ACR26 #GlobalSummit
A persistent knee monoarthritis in a 42M
Received amox/clav, then steroids, then MTX
#ACR26 #GlobalSummit
この試合地上波でやんなかったとか正気ですか？
www.youtube.com/watch?v=iMId...
www.youtube.com/watch?v=iMId...
【神コース】100点満点の軌道！ 新井直人のパーフェクトFK
YouTube video by Jリーグ公式チャンネル
www.youtube.com
October 28, 2026 at 12:50 PM
この試合地上波でやんなかったとか正気ですか？
www.youtube.com/watch?v=iMId...
www.youtube.com/watch?v=iMId...
Systematic review of CV outcomes w/ SGLT2 inhibitors- 5 studies, 11,190 IMID pts (SSc 25%, SLE 71%) SGLT2i use assoc w/ signif lower all-cause mortality and heart failure risk (no clear MI benefit). SGLT2i have establ use in NIDDM, CHF & CKD Pts. buff.ly/uBaeMHA
October 26, 2026 at 7:00 PM
Systematic review of CV outcomes w/ SGLT2 inhibitors- 5 studies, 11,190 IMID pts (SSc 25%, SLE 71%) SGLT2i use assoc w/ signif lower all-cause mortality and heart failure risk (no clear MI benefit). SGLT2i have establ use in NIDDM, CHF & CKD Pts. buff.ly/uBaeMHA
High TB & LTBI burden in Latin America. Review of PANLAR registry 590 IMID pts (54% GC, 44% bDMARDs (TNFi), 29% JAKi, 27% csDMARD). Only 430 (73%) had TB screening- 59 (14%) Dx w/ LTBI. @12 mos, 99 repeat TB screening - 5 new LTBI cases Dx. Only 2 (0.34%) had active TB. buff.ly/ORggLyM
Epidemiology of tuberculosis infection among Latin American patients with chronic inflammatory arthritis: data from the PANLAR registry of rheumatic diseases (PANRED) - Advances in Rheumatology
Objectives To evaluate the screening, diagnosis, and treatment of tuberculosis infection (TBI), as well as the occurrence of tuberculosis disease (TBD), in patients with chronic inflammatory…
buff.ly
October 26, 2026 at 9:00 PM
High TB & LTBI burden in Latin America. Review of PANLAR registry 590 IMID pts (54% GC, 44% bDMARDs (TNFi), 29% JAKi, 27% csDMARD). Only 430 (73%) had TB screening- 59 (14%) Dx w/ LTBI. @12 mos, 99 repeat TB screening - 5 new LTBI cases Dx. Only 2 (0.34%) had active TB. buff.ly/ORggLyM
Just because…🎶🎙️🎸🥁🎹🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊
#MorningMusic ☕️☕️☕️⛅️☁️💨
…try to have a great one folks😊🤞 Stay safe, strong & well🎶👊😎
m.youtube.com/watch?v=imid...
#MorningMusic ☕️☕️☕️⛅️☁️💨
…try to have a great one folks😊🤞 Stay safe, strong & well🎶👊😎
m.youtube.com/watch?v=imid...
I Did My Best
YouTube video by Soul Asylum - Topic
m.youtube.com
October 21, 2026 at 2:00 PM
Just because…🎶🎙️🎸🥁🎹🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊🔊
#MorningMusic ☕️☕️☕️⛅️☁️💨
…try to have a great one folks😊🤞 Stay safe, strong & well🎶👊😎
m.youtube.com/watch?v=imid...
#MorningMusic ☕️☕️☕️⛅️☁️💨
…try to have a great one folks😊🤞 Stay safe, strong & well🎶👊😎
m.youtube.com/watch?v=imid...
A helpful distinction for trainees: iberdomide binds cereblon more tightly than lenalidomide or pomalidomide and degrades Ikaros and Aiolos faster, which is why it can still work in IMiD-refractory disease. Nice to see Dr. Mikhael making the mechanism this approachable.
October 21, 2026 at 4:46 PM
A helpful distinction for trainees: iberdomide binds cereblon more tightly than lenalidomide or pomalidomide and degrades Ikaros and Aiolos faster, which is why it can still work in IMiD-refractory disease. Nice to see Dr. Mikhael making the mechanism this approachable.
did you also see this?
bsky.app/profile/imid...
bsky.app/profile/imid...
October 18, 2026 at 3:30 AM
did you also see this?
bsky.app/profile/imid...
bsky.app/profile/imid...
Assuming you’re not a neurologist or neurobiologist, explain how this makes any sense whatsoever.
October 6, 2026 at 11:25 AM
Assuming you’re not a neurologist or neurobiologist, explain how this makes any sense whatsoever.
Dr. Lawrence Boise’s summary of basic research at #IMS26 included a deep learning classifier for malignant plasma cells, whole proteomics insights into IMiD/CELMoD resistance, an AI-designed trispecific & transmitophagy in MM cells.
September 26, 2026 at 4:52 PM
Dr. Lawrence Boise’s summary of basic research at #IMS26 included a deep learning classifier for malignant plasma cells, whole proteomics insights into IMiD/CELMoD resistance, an AI-designed trispecific & transmitophagy in MM cells.
travis is getting fucking flamed on Twitter omg 😭
September 25, 2026 at 3:10 PM
they'res more in this thread too !
bsky.app/profile/imid...
bsky.app/profile/imid...
travis is getting fucking flamed on Twitter omg 😭
September 25, 2026 at 3:09 PM
they'res more in this thread too !
bsky.app/profile/imid...
bsky.app/profile/imid...
Resistance to less-potent IMiDs in myeloma can be rescued with more-potent IMiDs. IMiD resistance represents both a problem and opportunity, Vidyasgar Koduri, MD, PhD, said, who spoke abt CRBN mutation-driven IMiD resistance mechanisms. #IMS26
September 25, 2026 at 2:54 PM
Resistance to less-potent IMiDs in myeloma can be rescued with more-potent IMiDs. IMiD resistance represents both a problem and opportunity, Vidyasgar Koduri, MD, PhD, said, who spoke abt CRBN mutation-driven IMiD resistance mechanisms. #IMS26
👁️ ¿Conoces #MAIMID, el Marco de Actuación para las Enfermedades Inflamatorias Inmunomediadas?
Leer más 👇
Leer más 👇
Nuevo Marco de Actuación para las Enfermedades Inflamatorias Inmunomediadas: identifica seis necesidades estructurales
Expertos y pacientes impulsan un Marco de Actuación común para mejorar el diagnóstico precoz, la coordinación asistencial y la equidad en el abordaje de las Enfermedades Inflamatorias Inmunomediadas (IMID), que afectan a cerca de 2,5 millones de personas en España
www.consalud.es
September 25, 2026 at 11:11 AM
👁️ ¿Conoces #MAIMID, el Marco de Actuación para las Enfermedades Inflamatorias Inmunomediadas?
Leer más 👇
Leer más 👇
🩺 El nuevo Marco de Actuación para las IMID identifica 6 prioridades para mejorar la atención de los 2,5 millones de personas afectadas
Nuevo Marco de Actuación para las Enfermedades Inflamatorias Inmunomediadas: identifica seis necesidades estructurales
Expertos y pacientes impulsan un Marco de Actuación común para mejorar el diagnóstico precoz, la coordinación asistencial y la equidad en el abordaje de las Enfermedades Inflamatorias Inmunomediadas (IMID), que afectan a cerca de 2,5 millones de personas en España
www.consalud.es
September 24, 2026 at 8:17 AM
🩺 El nuevo Marco de Actuación para las IMID identifica 6 prioridades para mejorar la atención de los 2,5 millones de personas afectadas
Registration for the UK CARDIO-IMID Educational Conference 2026. All are welcome www.eventbrite.co.uk/e/uk-cardio-...
UK CARDIO-IMID Educational Conference 2026
Join colleagues from across the UK for a day of expert insights, practical learning and multidisciplinary discussion in cardio-rheumatology
www.eventbrite.co.uk
September 22, 2026 at 2:01 PM
Registration for the UK CARDIO-IMID Educational Conference 2026. All are welcome www.eventbrite.co.uk/e/uk-cardio-...
Registration is now open for the UK CARDIO-IMID Educational Conference 2026, taking part on Friday 13th November 2026 at the University of Leeds
September 22, 2026 at 2:00 PM
Registration is now open for the UK CARDIO-IMID Educational Conference 2026, taking part on Friday 13th November 2026 at the University of Leeds
Understanding HLA risk in immune-mediated inflammatory diseases requires antigen discovery #immunology
Understanding HLA risk in immune-mediated inflammatory diseases requires antigen discovery
Certain human leukocyte antigen (HLA) alleles occur more often in people with immune-mediated inflammatory diseases (IMIDs) than in unaffected individuals, making HLA one of the strongest inherited contributors to IMID risk. Yet how these alleles promote disease remains unclear. We argue that HLA risk has often been studied through allele-level properties or immunopeptidomic profiles without knowing which antigenic exposures matter. These approaches characterize peptide binding and presentation but rarely identify disease-relevant exposures. We propose that large-scale T cell receptor repertoire analysis provides a complementary route by identifying disease-associated clonotypes as antigenic footprints. When interpreted in their HLA context, these antigenic footprints can focus immunopeptidomic and functional studies on candidate antigens, turning HLA associations from statistical signals into testable mechanisms of disease.
dlvr.it
September 7, 2026 at 11:13 PM
Understanding HLA risk in immune-mediated inflammatory diseases requires antigen discovery #immunology
A week on from IMID 2026 and the follow ups are what is left.
What I did not expect: almost every good conversation at Booth 21 was about failure. Sublimation yield on hindered structures. Impurities in a host class. Lead time at 50 g.
Questions from people a supplier failed.
What I did not expect: almost every good conversation at Booth 21 was about failure. Sublimation yield on hindered structures. Impurities in a host class. Lead time at 50 g.
Questions from people a supplier failed.
August 31, 2026 at 1:31 AM
A week on from IMID 2026 and the follow ups are what is left.
What I did not expect: almost every good conversation at Booth 21 was about failure. Sublimation yield on hindered structures. Impurities in a host class. Lead time at 50 g.
Questions from people a supplier failed.
What I did not expect: almost every good conversation at Booth 21 was about failure. Sublimation yield on hindered structures. Impurities in a host class. Lead time at 50 g.
Questions from people a supplier failed.
Congratulations to the winners of the 10th UDC Pioneering Technology Award at IMID 2026.
Jae Min Jang, Dong Jin Shin and Jun Yeob Lee at Sungkyunkwan, with Bin Liu, Raju Lampande, Sritoma Paul, Claire Arneson and Stephen R. Forrest at Michigan.
We ran a highlight on Prof. Lee's work last week.
Jae Min Jang, Dong Jin Shin and Jun Yeob Lee at Sungkyunkwan, with Bin Liu, Raju Lampande, Sritoma Paul, Claire Arneson and Stephen R. Forrest at Michigan.
We ran a highlight on Prof. Lee's work last week.
August 31, 2026 at 1:05 AM
Congratulations to the winners of the 10th UDC Pioneering Technology Award at IMID 2026.
Jae Min Jang, Dong Jin Shin and Jun Yeob Lee at Sungkyunkwan, with Bin Liu, Raju Lampande, Sritoma Paul, Claire Arneson and Stephen R. Forrest at Michigan.
We ran a highlight on Prof. Lee's work last week.
Jae Min Jang, Dong Jin Shin and Jun Yeob Lee at Sungkyunkwan, with Bin Liu, Raju Lampande, Sritoma Paul, Claire Arneson and Stephen R. Forrest at Michigan.
We ran a highlight on Prof. Lee's work last week.
The authors included RRIDs in their in British Journal of Haematology paper! RRIDs improve reproducibility in scientific research. #reproducibility #accelerateopenscience #ReproducibleResearch
Cellular and molecular impacts of <fc>CELMoDs</fc> and <fc>IMiD</fc> on the induction of myeloid‐derived suppressor cells by myeloma cells
Read the full paper: Cellular and molecular impacts of <fc>CELMoDs</fc> and <fc>IMiD</fc> on the induction of myeloid‐derived suppressor cells by myeloma cells
doi.org
August 28, 2026 at 7:02 AM
The authors included RRIDs in their in British Journal of Haematology paper! RRIDs improve reproducibility in scientific research. #reproducibility #accelerateopenscience #ReproducibleResearch
Težko mi je, ko bo zgodovina pisala o nas kot edinih EU kolaborantih z genocidarji. Ne bodo pisali o sekti, pa prevarantskih oprodah. Pečat bo dobil cel narod. Imiđ, ki se ga še dolgo ne bomo znebili.
Kot bi nas polili s katranom in porinili v perje 😔
Kot bi nas polili s katranom in porinili v perje 😔
August 26, 2026 at 8:24 PM
Težko mi je, ko bo zgodovina pisala o nas kot edinih EU kolaborantih z genocidarji. Ne bodo pisali o sekti, pa prevarantskih oprodah. Pečat bo dobil cel narod. Imiđ, ki se ga še dolgo ne bomo znebili.
Kot bi nas polili s katranom in porinili v perje 😔
Kot bi nas polili s katranom in porinili v perje 😔
LG Display built its entire IMID 2026 stand around one idea: tandem. Two emitting units in series joined by charge generation layers, so each unit runs at about half the current density. Degradation is super linear in current, so lifetime rises faster than cost.
lamko.co.kr/lg-imid
lamko.co.kr/lg-imid
August 24, 2026 at 3:29 PM
LG Display built its entire IMID 2026 stand around one idea: tandem. Two emitting units in series joined by charge generation layers, so each unit runs at about half the current density. Degradation is super linear in current, so lifetime rises faster than cost.
lamko.co.kr/lg-imid
lamko.co.kr/lg-imid
Samsung mostra a IMID 2026 il primo OLED da 16" a 300 Hz: ecco i display del futuro - Tutta La Tecnologia www.tuttalatecnologia.it/samsung-most...
Samsung mostra a IMID 2026 il primo OLED da 16" a 300 Hz: ecco i display del futuro - Tutta La Tecnologia
Samsung Display porta alla IMID 2026 di Busan una nuova generazione di pannelli OLED destinati a diversi segmenti del mercato, dai laptop gaming agli smartphone pieghevoli, fino ai grandi display elas...
www.tuttalatecnologia.it
August 24, 2026 at 10:44 AM
Samsung mostra a IMID 2026 il primo OLED da 16" a 300 Hz: ecco i display del futuro - Tutta La Tecnologia www.tuttalatecnologia.it/samsung-most...